Literature DB >> 26631491

Antiatherosclerotic Effects of 1-Methylnicotinamide in Apolipoprotein E/Low-Density Lipoprotein Receptor-Deficient Mice: A Comparison with Nicotinic Acid.

Lukasz Mateuszuk1, Agnieszka Jasztal1, Edyta Maslak1, Marlena Gasior-Glogowska1, Malgorzata Baranska1, Barbara Sitek1, Renata Kostogrys1, Agnieszka Zakrzewska1, Agnieszka Kij1, Maria Walczak1, Stefan Chlopicki2.   

Abstract

1-Methylnicotinamide (MNA), the major endogenous metabolite of nicotinic acid (NicA), may partially contribute to the vasoprotective properties of NicA. Here we compared the antiatherosclerotic effects of MNA and NicA in apolipoprotein E (ApoE)/low-density lipoprotein receptor (LDLR)-deficient mice. ApoE/LDLR(-/-) mice were treated with MNA or NicA (100 mg/kg). Plaque size, macrophages, and cholesterol content in the brachiocephalic artery, endothelial function in the aorta, systemic inflammation, platelet activation, as well as the concentration of MNA and its metabolites in plasma and urine were measured. MNA and NicA reduced atherosclerotic plaque area, plaque inflammation, and cholesterol content in the brachiocephalic artery. The antiatherosclerotic actions of MNA and NicA were associated with improved endothelial function, as evidenced by a higher concentration of 6-keto-prostaglandin F1 α and nitrite/nitrate in the aortic ring effluent, inhibition of platelets (blunted thromboxane B2 generation), and inhibition of systemic inflammation (lower plasma concentration of serum amyloid P, haptoglobin). NicA treatment resulted in an approximately 2-fold higher concentration of MNA and its metabolites in urine and a 4-fold higher nicotinamide/MNA ratio in plasma, compared with MNA treatment. In summary; MNA displays pronounced antiatherosclerotic action in ApoE/LDLR(-/-) mice, an effect associated with an improvement in prostacyclin- and nitric oxide-dependent endothelial function, inhibition of platelet activation, inhibition of inflammatory burden in plaques, and diminished systemic inflammation. Despite substantially higher MNA availability after NicA treatment, compared with an equivalent dose of MNA, the antiatherosclerotic effect of NicA was not stronger. We suggest that detrimental effects of NicA or its metabolites other than MNA may limit beneficial effects of NicA-derived MNA.
Copyright © 2016 by The American Society for Pharmacology and Experimental Therapeutics.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26631491      PMCID: PMC6047228          DOI: 10.1124/jpet.115.228643

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  38 in total

1.  Effects of nicotinic acid on endothelial cells and platelets.

Authors:  Ksenija Stach; Friederike Zaddach; Xuan Duc Nguyen; Elif Elmas; Stefan Kralev; Christel Weiss; Martin Borggrefe; Thorsten Kälsch
Journal:  Cardiovasc Pathol       Date:  2011-05-31       Impact factor: 2.185

2.  Imaging of lipids in atherosclerotic lesion in aorta from ApoE/LDLR-/- mice by FT-IR spectroscopy and Hierarchical Cluster Analysis.

Authors:  Tomasz P Wrobel; Lukasz Mateuszuk; Stefan Chlopicki; Kamilla Malek; Malgorzata Baranska
Journal:  Analyst       Date:  2011-10-17       Impact factor: 4.616

Review 3.  Niacin and its metabolites: role of LC-MS/MS bioanalytical methods and update on clinical pharmacology. An overview.

Authors:  Ramesh Mullangi; Nuggehally R Srinivas
Journal:  Biomed Chromatogr       Date:  2010-11-05       Impact factor: 1.902

4.  Atherosclerosis: the importance of HDL cholesterol and prostacyclin: a role for niacin therapy.

Authors:  M H Luria
Journal:  Med Hypotheses       Date:  1990-05       Impact factor: 1.538

5.  Effects of oral niacin on endothelial dysfunction in patients with coronary artery disease: results of the randomized, double-blind, placebo-controlled INEF study.

Authors:  Ascan Warnholtz; Philipp Wild; Mir Abolfazl Ostad; Veronika Elsner; Fabian Stieber; Reinhard Schinzel; Ulrich Walter; Dirk Peetz; Karl Lackner; Stefan Blankenberg; Thomas Munzel
Journal:  Atherosclerosis       Date:  2008-08-12       Impact factor: 5.162

6.  Competitive binding of CREB and ATF2 to cAMP/ATF responsive element regulates eNOS gene expression in endothelial cells.

Authors:  Kazuo Niwano; Masashi Arai; Norimichi Koitabashi; Shiro Hara; Atai Watanabe; Kenichi Sekiguchi; Toru Tanaka; Tatsuya Iso; Masahiko Kurabayashi
Journal:  Arterioscler Thromb Vasc Biol       Date:  2006-02-23       Impact factor: 8.311

7.  Plasma and urine pharmacokinetics of niacin and its metabolites from an extended-release niacin formulation.

Authors:  R M Menon; M H Adams; M A González; D S Tolbert; J H Leu; E A Cefali
Journal:  Int J Clin Pharmacol Ther       Date:  2007-08       Impact factor: 1.366

Review 8.  Lipid-lowering agents that cause drug-induced hepatotoxicity.

Authors:  Sidharth S Bhardwaj; Naga Chalasani
Journal:  Clin Liver Dis       Date:  2007-08       Impact factor: 6.126

9.  Niacin inhibits vascular oxidative stress, redox-sensitive genes, and monocyte adhesion to human aortic endothelial cells.

Authors:  Shobha H Ganji; Shucun Qin; Linhua Zhang; Vaijinath S Kamanna; Moti L Kashyap
Journal:  Atherosclerosis       Date:  2008-05-09       Impact factor: 5.162

10.  Niacin Reduces Atherosclerosis Development in APOE*3Leiden.CETP Mice Mainly by Reducing NonHDL-Cholesterol.

Authors:  Susan Kühnast; Mieke C Louwe; Mattijs M Heemskerk; Elsbet J Pieterman; Jan B van Klinken; Sjoerd A A van den Berg; Johannes W A Smit; Louis M Havekes; Patrick C N Rensen; José W A van der Hoorn; Hans M G Princen; J Wouter Jukema
Journal:  PLoS One       Date:  2013-06-19       Impact factor: 3.240

View more
  12 in total

1.  1-methylnicotinamide and its structural analog 1,4-dimethylpyridine for the prevention of cancer metastasis.

Authors:  Agnieszka Blazejczyk; Marta Switalska; Stefan Chlopicki; Andrzej Marcinek; Jerzy Gebicki; Marcin Nowak; Anna Nasulewicz-Goldeman; Joanna Wietrzyk
Journal:  J Exp Clin Cancer Res       Date:  2016-07-13

2.  Activation of the nicotinamide N-methyltransferase (NNMT)-1-methylnicotinamide (MNA) pathway in pulmonary hypertension.

Authors:  Andrzej Fedorowicz; Łukasz Mateuszuk; Grzegorz Kopec; Tomasz Skórka; Barbara Kutryb-Zając; Agnieszka Zakrzewska; Maria Walczak; Andrzej Jakubowski; Magdalena Łomnicka; Ewa Słomińska; Stefan Chlopicki
Journal:  Respir Res       Date:  2016-08-31

3.  Serum N1-Methylnicotinamide is Associated With Coronary Artery Disease in Chinese Patients.

Authors:  Ming Liu; Jihong Chu; Yang Gu; Haibo Shi; Rusheng Zhang; Lingzhun Wang; Jiandong Chen; Le Shen; Peng Yu; Xiaohu Chen; Wenzheng Ju; Zhenxing Wang
Journal:  J Am Heart Assoc       Date:  2017-02-07       Impact factor: 5.501

4.  Functional and Biochemical Endothelial Profiling In Vivo in a Murine Model of Endothelial Dysfunction; Comparison of Effects of 1-Methylnicotinamide and Angiotensin-converting Enzyme Inhibitor.

Authors:  Anna Bar; Mariola Olkowicz; Urszula Tyrankiewicz; Edyta Kus; Krzysztof Jasinski; Ryszard T Smolenski; Tomasz Skorka; Stefan Chlopicki
Journal:  Front Pharmacol       Date:  2017-04-10       Impact factor: 5.810

5.  Degradation of Glycocalyx and Multiple Manifestations of Endothelial Dysfunction Coincide in the Early Phase of Endothelial Dysfunction Before Atherosclerotic Plaque Development in Apolipoprotein E/Low-Density Lipoprotein Receptor-Deficient Mice.

Authors:  Anna Bar; Marta Targosz-Korecka; Joanna Suraj; Bartosz Proniewski; Agnieszka Jasztal; Brygida Marczyk; Magdalena Sternak; Magdalena Przybyło; Anna Kurpińska; Maria Walczak; Renata B Kostogrys; Marek Szymonski; Stefan Chlopicki
Journal:  J Am Heart Assoc       Date:  2019-03-19       Impact factor: 5.501

6.  Multi-omic signatures of atherogenic dyslipidaemia: pre-clinical target identification and validation in humans.

Authors:  Mariola Olkowicz; Izabela Czyzynska-Cichon; Natalia Szupryczynska; Renata B Kostogrys; Zdzislaw Kochan; Janusz Debski; Michal Dadlez; Stefan Chlopicki; Ryszard T Smolenski
Journal:  J Transl Med       Date:  2021-01-06       Impact factor: 5.531

7.  Enhanced Muscle Strength in Dyslipidemic Mice and Its Relation to Increased Capacity for Fatty Acid Oxidation.

Authors:  Marta Tomczyk; Alicja Braczko; Patrycja Jablonska; Adriana Mika; Kamil Przyborowski; Agata Jedrzejewska; Oliwia Krol; Filip Kus; Tomasz Sledzinski; Stefan Chlopicki; Ewa M Slominska; Ryszard T Smolenski
Journal:  Int J Mol Sci       Date:  2021-11-12       Impact factor: 5.923

8.  Distinct Chemical Changes in Abdominal but Not in Thoracic Aorta upon Atherosclerosis Studied Using Fiber Optic Raman Spectroscopy.

Authors:  Krzysztof Czamara; Zuzanna Majka; Magdalena Sternak; Mateusz Koziol; Renata B Kostogrys; Stefan Chlopicki; Agnieszka Kaczor
Journal:  Int J Mol Sci       Date:  2020-07-08       Impact factor: 5.923

Review 9.  Therapeutic Potential of Emerging NAD+-Increasing Strategies for Cardiovascular Diseases.

Authors:  Noemi Rotllan; Mercedes Camacho; Mireia Tondo; Elena M G Diarte-Añazco; Marina Canyelles; Karen Alejandra Méndez-Lara; Sonia Benitez; Núria Alonso; Didac Mauricio; Joan Carles Escolà-Gil; Francisco Blanco-Vaca; Josep Julve
Journal:  Antioxidants (Basel)       Date:  2021-12-03

10.  Esterase-Sensitive Prodrugs of a Potent Bisubstrate Inhibitor of Nicotinamide N-Methyltransferase (NNMT) Display Cellular Activity.

Authors:  Matthijs J van Haren; Yongzhi Gao; Ned Buijs; Roberto Campagna; Davide Sartini; Monica Emanuelli; Lukasz Mateuszuk; Agnieszka Kij; Stefan Chlopicki; Pol Escudé Martinez de Castilla; Raymond Schiffelers; Nathaniel I Martin
Journal:  Biomolecules       Date:  2021-09-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.